Bookmark and Share
Print Friendly and PDF

Peter Buchwald, Ph.D.

Peter Buchwald, Ph.D. interview

 

Alternate content supporting alternate title

Get Adobe Flash player

Transcript of interview:

Delivering immunosuppressive drugs only to implanted devices 

“If we can manage to have immunosuppression then only within this device, that would be a great advantage because first of all we need a much, much smaller dose. We don’t have to use the drug all over the body. It only has to be in the very small device, which is like thousands, or even less portion volume of the whole body, and somehow infuse it just locally straight in this device.” 

Using small molecules to target and block immune attack

“Current immunosuppressive therapies are administered systemically and they have either undesired toxic or side effects, which in the long run are unavoidable. So, what we are trying to do is target a very specific, co-stimulatory pathway so it will act only specifically on the immune response directed to the islets.”   

 

Diabetes Research Institute Foundation
200 S. Park Road, Suite 100
Hollywood, FL 33021
[P]   (954) 964-4040
[TF] (800) 321-3437
[F]   (954) 964-7036

Join Us on FacebookWatch us on YouTubeFollow Us on Twitter

BBB Wise Giving Alliance Accredited Charity  The Diabetes Research Institute Foundation is a Gold Level Participant on the GuideStar Exchange.  The Blue Circle - the global symbol for diabetes

Home | LoginDRInsider Sign Up | Site MapSite Search Contact UsDirectionsRecommended LinksPrivacy and Terms of Use | Mission Statements

© 2016 Diabetes Research Institute Foundation - National Office: 200 S. Park Road, Suite 100, Hollywood, FL 33021 - (954) 964-4040

Miller School of Medicine